Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -68.96% is 192% below its 5-year average of -23.58%, near the low end of its 5-year range (-68.96%–51.32%).
515.42% below its 12-month average of 16.60%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 14.05%.
RETURN ON ASSETS (ROA)
-68.96%
RETURN ON ASSETS (ROA) AVG TTM
16.60%
RETURN ON ASSETS (ROA) AVG 3Y
-13.89%
RETURN ON ASSETS (ROA) AVG 5Y
-23.58%
RETURN ON ASSETS (ROA) AVG 10Y
-36.85%
RETURN ON ASSETS (ROA) AVG 15Y
-47.88%
RETURN ON ASSETS (ROA) AVG 20Y
-43.36%
CURRENT VS TTM AVG
-515.42%
CURRENT VS 3Y AVG
-396.56%
CURRENT VS 5Y AVG
-192.47%
CURRENT VS 10Y AVG
-87.13%
CURRENT VS 15Y AVG
-44.02%
CURRENT VS 20Y AVG
-59.03%
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-156.36%
vs the sector median at left
BioCryst Pharmaceuticals, Inc.
Market Cap
$2.06B
Return on Assets (ROA)
-68.96%
TTM Avg
16.60%
3Y Avg
-13.89%
5Y Avg
-23.58%
Market Cap
$2.07B
Return on Assets (ROA)
-11.31%
TTM Avg
-8.55%
3Y Avg
-34.29%
5Y Avg
-31.66%
Market Cap
$2.05B
Return on Assets (ROA)
14.58%
TTM Avg
11.33%
3Y Avg
2.89%
5Y Avg
-3.84%
Market Cap
$2.02B
Return on Assets (ROA)
-44.98%
TTM Avg
-76.52%
3Y Avg
-94.59%
5Y Avg
-76.85%
Market Cap
$2.02B
Return on Assets (ROA)
39.65%
TTM Avg
19.63%
3Y Avg
0.51%
5Y Avg
-8.90%
Market Cap
$2.11B
Return on Assets (ROA)
7.23%
TTM Avg
5.94%
3Y Avg
5.72%
5Y Avg
5.23%
Market Cap
$2.01B
Return on Assets (ROA)
-3.14%
TTM Avg
-22.75%
3Y Avg
-10.43%
5Y Avg
-6.58%
Market Cap
$2.00B
Return on Assets (ROA)
-11.00%
TTM Avg
-5.98%
3Y Avg
-9.46%
5Y Avg
-10.43%
Market Cap
$1.97B
Return on Assets (ROA)
-6.55%
TTM Avg
-5.28%
3Y Avg
-5.65%
5Y Avg
-2.06%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioCryst Pharmaceuticals, Inc. (BCRX) | $2.06B | -68.96% | 16.60% | -13.89% | -23.58% |
| Alvotech (ALVO)vs › | $2.07B | -11.31% | -8.55% | -34.29% | -31.66% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 14.58% | 11.33% | 2.89% | -3.84% |
| Immunome, Inc. (IMNM)vs › | $2.02B | -44.98% | -76.52% | -94.59% | -76.85% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 39.65% | 19.63% | 0.51% | -8.90% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 7.23% | 5.94% | 5.72% | 5.23% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | -3.14% | -22.75% | -10.43% | -6.58% |
| AxoGen, Inc. (AXGN)vs › | $2.00B | -11.00% | -5.98% | -9.46% | -10.43% |
| Azenta, Inc. (AZTA)vs › | $1.97B | -6.55% | -5.28% | -5.65% | -2.06% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | -11.05% | -19.34% | -25.88% | -26.23% |
ROA
-69.0%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 51.32% |
| 2024-12-31 | -18.12% |
| 2023-12-31 | -43.82% |
| 2022-12-31 | -44.93% |
| 2021-12-31 | -31.30% |
| 2020-12-31 | -54.62% |
| 2019-12-31 | -62.13% |
| 2018-12-31 | -68.95% |
| 2017-12-31 | -36.90% |
| 2016-12-31 | -61.38% |
| 2015-12-31 | -34.54% |
| 2014-12-31 | -33.02% |
| 2013-12-31 | -61.61% |
| 2012-12-31 | -68.04% |
| 2011-12-31 | -69.27% |
| 2010-12-31 | -29.60% |
| 2009-12-31 | -9.46% |
| 2008-12-31 | -29.20% |
| 2007-12-31 | -20.36% |
| 2006-12-31 | -63.69% |
| 2005-12-31 | -26.30% |
| 2004-12-31 | -65.00% |
| 2003-12-31 | -42.20% |
| 2002-12-31 | -40.99% |
| 2001-12-31 | -8.44% |
| 2000-12-31 | -16.35% |
| 1999-12-31 | -7.22% |
| 1998-12-31 | -16.49% |
| 1997-12-31 | -40.00% |
| 1996-12-31 | -20.75% |
